An HLA-binding prediction, a detected peptide and a T cell response provide different kinds of evidence. A useful validation strategy connects them without treating any one result as a complete answer.
Vesicles released by dendritic cells offer a way to study how immune information is transferred between cells. Their identity, composition and activity must be measured rather than inferred from the source cell.
A renewable cell resource is valuable when its identity, antigen configuration and functional behavior can be traced across experiments. Banking organizes that evidence; it does not create biological consistency on its own.
γδ T cells broaden the ways immune recognition can be studied. Their diversity makes subset definition, mechanism and functional evidence central to any proposed experiment that uses an APC.
Tumor-infiltrating lymphocytes are a heterogeneous starting material. The central experimental question is which cells recognize the tumor and whether that activity is preserved during culture.
Studies that frame antigen selection, TIL, DC-based and NK cell experiments. Findings are as reported by each study, in its own patients and conditions. They do not describe eDC performance.
Topic
Study
Reported finding
Source
Antigen selection
Wells DK et al. Cell. 2020;183:818–834 (TESLA)
37 of 608 candidates prioritized by prediction (6%) were recognized by T cells. Binding affinity, tumor abundance and binding stability together improved prediction.
Parkhurst MR et al. Cancer Discov. 2019;9:1022–1035
In 75 patients with gastrointestinal cancers, 1.6% of mutated gene products were recognized by autologous TIL, and neoantigen-reactive TIL were found in 62 of 75 patients.
Randomized phase 3 of sipuleucel-T, an autologous product containing antigen-presenting cells, 512 patients with prostate cancer: median overall survival 25.8 versus 21.7 months (HR 0.78).